SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Mike Grey will be moderating a panel discussion on strategies for CNS drug and device development at the Neurotech Investing and Partnering Conference in San Francisco, CA.
News | 05. 10. 2011
